166 related articles for article (PubMed ID: 9802348)
21. MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors.
Abramovich CM; Prayson RA
Hum Pathol; 1998 Dec; 29(12):1420-7. PubMed ID: 9865827
[TBL] [Abstract][Full Text] [Related]
22. Molecular markers for predicting prostate cancer stage and survival.
Dunsmuir WD; Gillett CE; Meyer LC; Young MP; Corbishley C; Eeles RA; Kirby RS
BJU Int; 2000 Nov; 86(7):869-78. PubMed ID: 11069416
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathological features, MIB-1 labeling index and apoptotic index in recurrent astrocytic tumors.
Ralte AM; Sharma MC; Karak AK; Mehta VS; Sarkar C
Pathol Oncol Res; 2001; 7(4):267-78. PubMed ID: 11882906
[TBL] [Abstract][Full Text] [Related]
24. Predicting the recurrence of ependymomas from the bromodeoxyuridine labeling index.
Asai A; Hoshino T; Edwards MS; Davis RL
Childs Nerv Syst; 1992 Aug; 8(5):273-8. PubMed ID: 1394266
[TBL] [Abstract][Full Text] [Related]
25. MIB-1 labeling index in nonpilocytic astrocytoma of childhood: a study of 101 cases.
Ho DM; Wong TT; Hsu CY; Ting LT; Chiang H
Cancer; 1998 Jun; 82(12):2459-66. PubMed ID: 9635540
[TBL] [Abstract][Full Text] [Related]
26. The proliferative potential of human ependymomas measured by in situ bromodeoxyuridine labeling.
Nagashima T; Hoshino T; Cho KG; Edwards MS; Hudgins RJ; Davis RL
Cancer; 1988 Jun; 61(12):2433-8. PubMed ID: 3284636
[TBL] [Abstract][Full Text] [Related]
27. Proliferation- and apoptosis-related proteins in intracranial ependymomas: an immunohistochemical analysis.
Verstegen MJ; Leenstra DT; Ijlst-Keizers H; Bosch DA
J Neurooncol; 2002 Jan; 56(1):21-8. PubMed ID: 11949823
[TBL] [Abstract][Full Text] [Related]
28. MIB-1 labeling index in astrocytic tumors--a clinicopathologic study.
Neder L; Colli BO; Machado HR; Carlotti CG; Santos AC; Chimelli L
Clin Neuropathol; 2004; 23(6):262-70. PubMed ID: 15584210
[TBL] [Abstract][Full Text] [Related]
29. Spinal ependymomas. Part 2: Ependymomas of the filum terminale.
Klekamp J
Neurosurg Focus; 2015 Aug; 39(2):E7. PubMed ID: 26235024
[TBL] [Abstract][Full Text] [Related]
30. Proliferative activity as measured by MIB-1 labeling index and long-term outcome of visual pathway astrocytomas in children.
Czech T; Slavc I; Aichholzer M; Haberler C; Dietrich W; Dieckmann K; Koos W; Budka H
J Neurooncol; 1999 Apr; 42(2):143-50. PubMed ID: 10421072
[TBL] [Abstract][Full Text] [Related]
31. Disseminated ependymomas of the central nervous system.
Rezai AR; Woo HH; Lee M; Cohen H; Zagzag D; Epstein FJ
J Neurosurg; 1996 Oct; 85(4):618-24. PubMed ID: 8814165
[TBL] [Abstract][Full Text] [Related]
32. Anaplastic pleomorphic xanthoastrocytoma.
Prayson RA; Morris HH
Arch Pathol Lab Med; 1998 Dec; 122(12):1082-6. PubMed ID: 9870856
[TBL] [Abstract][Full Text] [Related]
33. Correlation between the bromodeoxyuridine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas.
Onda K; Davis RL; Shibuya M; Wilson CB; Hoshino T
Cancer; 1994 Oct; 74(7):1921-6. PubMed ID: 7521787
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical markers for prognosis of ependymal neoplasms.
Korshunov A; Golanov A; Timirgaz V
J Neurooncol; 2002 Jul; 58(3):255-70. PubMed ID: 12187959
[TBL] [Abstract][Full Text] [Related]
35. Surgical outcomes in spinal cord ependymomas and the importance of extent of resection in children and young adults.
Safaee M; Oh MC; Mummaneni PV; Weinstein PR; Ames CP; Chou D; Berger MS; Parsa AT; Gupta N
J Neurosurg Pediatr; 2014 Apr; 13(4):393-9. PubMed ID: 24506340
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases.
Korshunov A; Golanov A; Timirgaz V
J Neurol Sci; 2000 Aug; 177(1):72-82. PubMed ID: 10967185
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathologic features of anaplastic myxopapillary ependymomas.
Lee JC; Sharifai N; Dahiya S; Kleinschmidt-DeMasters BK; Rosenblum MK; Reis GF; Samuel D; Siongco AM; Santi M; Storm PB; Ferris SP; Bollen AW; Pekmezci M; Solomon DA; Tihan T; Perry A
Brain Pathol; 2019 Jan; 29(1):75-84. PubMed ID: 30417460
[TBL] [Abstract][Full Text] [Related]
38. Expression of mos in ependymal gliomas.
Athanasiou A; Perunovic B; Quilty RD; Gorgoulis VG; Kittas C; Love S
Am J Clin Pathol; 2003 Nov; 120(5):699-705. PubMed ID: 14608895
[TBL] [Abstract][Full Text] [Related]
39. Expression of cyclo-oxygenase-2 in ependymal tumors.
Roma AA; Prayson RA
Neuropathology; 2006 Oct; 26(5):422-8. PubMed ID: 17080719
[TBL] [Abstract][Full Text] [Related]
40. Expression of cyclin A and topoisomerase IIalpha of oligodendrogliomas is correlated with tumour grade, MIB-1 labelling index and survival.
Park SH; Suh YL
Histopathology; 2003 Apr; 42(4):395-402. PubMed ID: 12653952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
